- Home
- MOBX vs SKYE Comparison
MOBX vs SKYE Comparison
Compare MOBX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- SKYE
- Stock Information
- Founded
- MOBX 2020
- SKYE 2012
- Country
- MOBX United States
- SKYE United States
- Employees
- MOBX N/A
- SKYE N/A
- Industry
- MOBX
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- SKYE Health Care
- Exchange
- MOBX Nasdaq
- SKYE Nasdaq
- Market Cap
- MOBX 52.0M
- SKYE 44.9M
- IPO Year
- MOBX N/A
- SKYE N/A
- Fundamental
- Price
- MOBX $0.47
- SKYE $1.31
- Analyst Decision
- MOBX
- SKYE Strong Buy
- Analyst Count
- MOBX 0
- SKYE 5
- Target Price
- MOBX N/A
- SKYE $14.75
- AVG Volume (30 Days)
- MOBX 1.8M
- SKYE 303.2K
- Earning Date
- MOBX 12-18-2025
- SKYE 11-10-2025
- Dividend Yield
- MOBX N/A
- SKYE N/A
- EPS Growth
- MOBX N/A
- SKYE N/A
- EPS
- MOBX N/A
- SKYE N/A
- Revenue
- MOBX $10,984,000.00
- SKYE N/A
- Revenue This Year
- MOBX N/A
- SKYE N/A
- Revenue Next Year
- MOBX N/A
- SKYE N/A
- P/E Ratio
- MOBX N/A
- SKYE N/A
- Revenue Growth
- MOBX 180.13
- SKYE N/A
- 52 Week Low
- MOBX $0.40
- SKYE $1.14
- 52 Week High
- MOBX $2.47
- SKYE $5.75
- Technical
- Relative Strength Index (RSI)
- MOBX 32.53
- SKYE 39.90
- Support Level
- MOBX $0.43
- SKYE $1.17
- Resistance Level
- MOBX $0.47
- SKYE $1.46
- Average True Range (ATR)
- MOBX 0.06
- SKYE 0.10
- MACD
- MOBX -0.00
- SKYE 0.04
- Stochastic Oscillator
- MOBX 18.40
- SKYE 36.90
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.